Qvick, Alvida https://orcid.org/0000-0001-6688-947X
Andersson, Elin
Oldaeus Almerén, Anna
Waenerlund, Max
Stenmark, Bianca
Karlsson, Christina
Karlsson, Mats G.
Helenius, Gisela
Clinical trials referenced in this document:
Documents that mention this clinical trial
Sensitive and Specific Droplet Digital PCR Assays for Circulating Tumor HPV DNA: Development, Validation, and Clinical Application in HPV-Associated Cancers
https://doi.org/10.1007/s40291-024-00743-9
Funding for this research was provided by:
Örebro County Council Research committee
Nyckelfonden-Örebro University Hospital Research Foundation
Lions fund for cancer research Uppsala-Örebro
Örebro University
Örebro University
Article History
Accepted: 20 August 2024
First Online: 26 September 2024
Declarations
:
: Conceptualization: G.H., A.O.A., and A.Q.; methodology: A.Q., E.A., and G.H..; validation: A.Q., E.A., and G.H.; formal analysis: A.Q., E.A., A.O.A., M.W., and G.H; investigation: A.Q., E.A., A.O.A., and M.K.; resources: G.H.; data curation: E.A., A.Q., A.O.A., M.W., and M.K.; writing—original draft preparation: A.Q.; writing—review and editing: A.Q., E.A., A.O.A., M.W., B.S., C.K., and G.H.; visualization: M.W. and A.Q.; supervision: G.H.; project administration: A.Q. and G.H.; funding acquisition: G.H. and A.O.A. All authors have read and agreed to the published version of the manuscript.
: Open access funding provided by Örebro University. This work was funded by the Örebro County Council Research committee, Nyckelfonden-Örebro University Hospital Research Foundation, Lions fund for cancer research Uppsala-Örebro, and Uppsala-Örebro Regional research council.
: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Review Board (2019-0656/2022-02405-02).
: Written informed consent was obtained from all research subjects involved in the study. For cfDNA samples used as technical controls, oral informed consent was obtained from all donors and samples were then anonymized and pooled before analysis. For FFPE samples used as technical controls, residual extracted DNA from clinical routine was anonymized before analysis. .
: The majority of data used in this study is presented in Online resource 4. Raw data is available upon reasonable request.
: Not applicable.
: The raw data used for the data analysis under Sect. <i> Assay development</i> was generated at SAGA Diagnostics. SAGA Diagnostics had no role in design of the study, interpretation of data, in the writing of the manuscript, or in the decision to publish the results. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. The authors declare no conflict of interest.